Literature DB >> 16644766

Remission in depression: definition and initial treatment approaches.

Joshua A Israel1.   

Abstract

Although remission is recognized as the optimal outcome of treatment for depression, remission lacks a universally accepted definition. This is partly due to the lack of objective biologic markers or tests that confirm a response to treatment and no well-defined end points of treatment. Significant symptoms may still exist even though patients may have a full response as measured by currently available standardized psychiatric rating scales. In addition, many patients may experience marked improvement in depressive symptoms but still have impaired psychosocial and work function. Wellness should be determined by evaluating a combination of three key domains: symptoms, functional status and pathophysiologic changes. In choosing an initial medication for depression, physicians are often guided by a mix of evidence-based medicine and unvalidated or even inaccurate clinical lore. In general, most available agents have comparable effectiveness; however, the subtype of depression and age of the patient should be considered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644766     DOI: 10.1177/1359786806064306

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  18 in total

1.  Calibration of response and remission cut-points on the Beck Depression Inventory-Second Edition for monitoring seasonal affective disorder treatment outcomes.

Authors:  Gloria M Reeves; Kelly J Rohan; Patricia Langenberg; Soren Snitker; Teodor T Postolache
Journal:  J Affect Disord       Date:  2012-01-25       Impact factor: 4.839

2.  Combining Stimulants and Monoamine Oxidase Inhibitors: A Reexamination of the Literature and a Report of a New Treatment Combination.

Authors:  Joshua A Israel
Journal:  Prim Care Companion CNS Disord       Date:  2015-12-10

3.  Mental Health in Allergic Rhinitis: Depression and Suicidal Behavior.

Authors:  Ameya U Amritwar; Christopher A Lowry; Lisa A Brenner; Andrew J Hoisington; Robert Hamilton; John W Stiller; Teodor T Postolache
Journal:  Curr Treat Options Allergy       Date:  2017-03-25

Review 4.  Partial remission, residual symptoms, and relapse in depression.

Authors:  E S Paykel
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

5.  Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories.

Authors:  Andrew J Cutler; Carl P Gommoll; Changzheng Chen; William M Greenberg; Adam Ruth
Journal:  Prim Care Companion CNS Disord       Date:  2015-06-11

6.  Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.

Authors:  David Bakish; Anjana Bose; Carl Gommoll; Changzheng Chen; Rene Nunez; William M Greenberg; Michael Liebowitz; Arif Khan
Journal:  J Psychiatry Neurosci       Date:  2014-01       Impact factor: 6.186

7.  A Bayesian approach to joint modeling of matrix-valued imaging data and treatment outcome with applications to depression studies.

Authors:  Bei Jiang; Eva Petkova; Thaddeus Tarpey; R Todd Ogden
Journal:  Biometrics       Date:  2019-11-14       Impact factor: 2.571

8.  Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.

Authors:  Somaia Mohamed; Gary R Johnson; Peijun Chen; Paul B Hicks; Lori L Davis; Jean Yoon; Theresa C Gleason; Julia E Vertrees; Kimberly Weingart; Ilanit Tal; Alexandra Scrymgeour; David D Lawrence; Beata Planeta; Michael E Thase; Grant D Huang; Sidney Zisook; Sanjai D Rao; Patricia D Pilkinton; James A Wilcox; Ali Iranmanesh; Mamta Sapra; George Jurjus; James P Michalets; Muhammed Aslam; Thomas Beresford; Keith D Anderson; Ronald Fernando; Sriram Ramaswamy; John Kasckow; Joseph Westermeyer; Gihyun Yoon; D Cyril D'Souza; Gunnar Larson; William G Anderson; Mary Klatt; Ayman Fareed; Shabnam I Thompson; Carlos J Carrera; Solomon S Williams; Timothy M Juergens; Lawrence J Albers; Clifford S Nasdahl; Gerardo Villarreal; Julia L Winston; Cristobal A Nogues; K Ryan Connolly; Andre Tapp; Kari A Jones; Gauri Khatkhate; Sheetal Marri; Trisha Suppes; Joseph LaMotte; Robin Hurley; Aimee R Mayeda; Alexander B Niculescu; Bernard A Fischer; David J Loreck; Nicholas Rosenlicht; Steven Lieske; Mitchell S Finkel; John T Little
Journal:  JAMA       Date:  2017-07-11       Impact factor: 56.272

9.  A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.

Authors:  Angelo Sambunaris; Anjana Bose; Carl P Gommoll; Changzheng Chen; William M Greenberg; David V Sheehan
Journal:  J Clin Psychopharmacol       Date:  2014-02       Impact factor: 3.153

10.  Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.

Authors:  Angelo Sambunaris; Carl Gommoll; Changzheng Chen; William M Greenberg
Journal:  Int Clin Psychopharmacol       Date:  2014-07       Impact factor: 1.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.